New pill HMPL-506 enters human testing for Hard-to-Treat leukemias

NCT ID NCT06387082

Recruiting now Disease control Sponsor: Hutchmed Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tests an experimental oral drug called HMPL-506 in about 132 adults with specific types of leukemia (AML or ALL) that have come back or not responded to treatment. The main goal is to check safety and find the right dose. Researchers will also look for signs that the drug is shrinking the cancer. The drug is taken daily in 28-day cycles until the disease gets worse or side effects become too much.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HMPL-506 (oral tablet)
What this could lead to: If it works, this could point toward a new treatment option for certain types of leukemia that have not responded to standard therapy.
What could go wrong: This is a very early Phase 1 trial with only 132 participants. The main goal is safety, not effectiveness. Many drugs fail at this stage, and side effects may be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGICAL MALIGNANCIES

Contacts and locations

Locations

Anhui Provincial Hospital
RECRUITING

Hefei, China
Blood Diseases Hospital, Chinese Academy of medical Sciences
RECRUITING

Tianjin, China
First Affiliated Hospital of Chongqing Medical University
RECRUITING

Chongqing, China
Fujian Medical University Union Hospital
NOT_YET_RECRUITING

Fuzhou, China
Henan Cancer Hospital
RECRUITING

Zhengzhou, China
Nanfang Hospital, Southern Medical University
RECRUITING

Guangzhou, China
Qilu Hospital of Shandong University
RECRUITING

Jinan, China
Shengjing Hospital of China Medical University
RECRUITING

Shenyang, China
Sun Yat-sen University Cancer Center
NOT_YET_RECRUITING

Guangzhou, China
The Affiliated Hospital of Guizhou Medical University
NOT_YET_RECRUITING

Guiyang, China
The First Affiliated Hospital of Soochow University
RECRUITING

Suzhou, China
The First Affiliated Hospital with Nanjing Medical University
RECRUITING

Nanjing, China
The First Affiliated Hospital, Zhejiang University
RECRUITING

Hangzhou, China
Tianjin People's Hospital
RECRUITING

Tianjin, China
Wuhan Union Hospital of China
RECRUITING

Wuhan, China
Xiangya Hospital of Central South University
RECRUITING

Changsha, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.